MedTrace Logo

Comparison of Time to Extubation Using Sugammadex or Neostigmine

NCT04606901 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2024-03-13

Study results available
· View outcomes & findings →

Summary

A prospective blinded randomized clinical trial to compare time to extubation using Sugammadex versus Neostigmine/glycopyrrolate as reversal agents after use of neuromuscular blockade agents in an outpatient bronchoscopy suite.

Conditions

Interventions

DRUG

neostigmine/glycopyrrolate

neuromuscular blockade reversal agents

DRUG

sugammadex

neuromuscular blockade reversal agent

Sponsors & Collaborators

Principal Investigators

  • Ellen Hauck, DO PhD · Lewis Katz School of Medicine at Temple University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-08
Primary Completion
2023-07-30
Completion
2023-07-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04606901 on ClinicalTrials.gov